Chester County News and Community Website
PLYMOUTH MEETING, PA — INOVIO (NASDAQ: INO) has unveiled promising peer-reviewed results from its Phase 1/2 clinical trial for INO-3107, a cutting-edge DNA medicine designed to treat recurrent respiratory papillomatosis (RRP). …
INOVIO’s INO-3107 Shows Powerful Potential for Treating Recurrent Respiratory Papillomatosis Read More PLYMOUTH MEETING, PA — INOVIO (NASDAQ: INO) has announced that new research on its investigational immunotherapy, INO-3107, will be presented at the American Association for Cancer Research – Immuno-Oncology conference from …
INOVIO to Highlight Breakthrough Immunotherapy Data at AACR Conference Read More PLYMOUTH MEETING, PA — INOVIO (NASDAQ: INO) has announced its participation in the Oppenheimer 35th Annual Healthcare Life Sciences Conference. Dr. Jacqueline Shea, the company’s President and CEO, along with Dr. …
INOVIO to Present at Oppenheimer Healthcare Life Sciences Conference Read More PLYMOUTH MEETING, PA — INOVIO (NASDAQ: INO) revealed its strategic milestones for 2025, positioning the company for significant advancements as it aims to become a commercial-stage biotechnology leader. Central to this …
INOVIO Targets 2025 as Transformational Year with Major Progress on INO-3107 Read More PLYMOUTH MEETING, PA — INOVIO (NASDAQ: INO) has announced new data from a retrospective trial showcasing the long-term benefits of its investigational therapy, INO-3107, for patients with Recurrent Respiratory Papillomatosis (RRP). …
INOVIO Reports Promising Long-Term Data for INO-3107 in Treating RRP Read More PLYMOUTH MEETING, PA — INOVIO (NASDAQ: INO) has announced a stock option grant to a newly hired employee under its 2022 Inducement Plan. The award was approved by INOVIO’s Compensation …
INOVIO Grants Equity Award Under 2022 Inducement Plan Read More PLYMOUTH MEETING, PA — INOVIO (NASDAQ: INO) has released its financial results for the third quarter of 2024, alongside updates on significant developments, particularly concerning its lead product candidate, INO-3107. …
INOVIO Reports Third-Quarter Financial Results and Updates on INO-3107 Progress Read More PLYMOUTH MEETING, PA — INOVIO (NASDAQ: INO) has unveiled encouraging new immunology data for its lead product candidate, INO-3107, which is designed to treat recurrent respiratory papillomatosis (RRP), a condition caused …
INOVIO Announces Promising Immunology Data for INO-3107 in RRP Treatment Read More PLYMOUTH MEETING, PA — INOVIO (NASDAQ: INO) has announced new data for its leading candidate, INO-3107, which could transform the treatment of recurrent respiratory papillomatosis (RRP). These findings, shared at the …
INOVIO Unveils Promising Data for INO-3107 in Treating RRP Read More PLYMOUTH MEETING, PA — INOVIO (NASDAQ: INO) has recently issued equity grants to new employees as part of its 2022 Inducement Plan. Aimed at attracting top talent, these inducement grants are …
INOVIO Announces Equity Grants for New Employees Under 2022 Inducement Plan Read More